MAPK8 and metabolic syndrome: Therefore, all the described phytochemicals in this review, which act as PPARγ agonists, may be suitable for the treatment of metabolic syndrome together with other compounds that can suppress inflammatory responses in a PPARγ-independent manner, by directly inhibiting NF-κB or JNK signaling.